Efficacy of osimertinib in advanced EGFR-mutated non-small cell lung cancer in first-line and second-line therapy (Tokushukai REAl-world Data project: TREAD 01)
Not Applicable
Recruiting
- Conditions
- advanced EGFR-mutated non-small cell lung cancer
- Registration Number
- JPRN-UMIN000050552
- Lead Sponsor
- Shonan Fujisawa Tokushukai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
EExclusion criteria include: de novo EGFR T790 M mutation, active multiple cancers, failure to provide informed consent (opting to opt-out), poor data extraction (e.g., missing details of previous cancer treatment at other hospitals or individual patient data), simultaneous and metachronous double cancers other than in situ/intramucosal cancer cured by local treatment or endoscopic lesions diagnosed as in situ cancer, and disease-free for 5 years or less.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method OS
- Secondary Outcome Measures
Name Time Method